The primary objective of this study is to describe the rate of local control in patients with
her-2 positive early stage breast cancer with a complete response to chemotherapy and
lumpectomy alone.

The primary objective of this study is to document lymphedema rates in patients requiring
regional nodal irradiation (RNI) who receive hypofractionated radiation as compared to
conventional radiation.

The purpose of this study is determine if the triplet combination of ribociclib, everolimus
and exemastane is effective in the treatment of locally advanced/metastatic breast cancer
following treatment with a CDK 4/6 inhibitor

This randomized phase III trial studies standard or comprehensive radiation therapy in
treating patients with early-stage breast cancer who have undergone surgery. Radiation
therapy uses high-energy x rays to kill tumor cells. It is not yet known whether
comprehensive radiation therapy is more effective than standard radiation therapy in
treating patients with breast cancer

This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole,
letrozole, or exemestane with or without chemotherapy work in treating patients with breast
cancer that has spread from where it began in the breast to surrounding normal tissue
(invasive). Estrogen can cause the growth of breast cancer cells. Hormone therapy, using
tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor
cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight
breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. It is not yet known whether
giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with
combination chemotherapy in treating patients with breast cancer.

The overall goal of this project is to develop an integrative system of breast cancer risk
assessment based on epidemiologic and biologic risk variables, as well as to develop or
refine risk biomarkers which may be useful in predicting and monitoring response to
prevention interventions.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or
exemestane, may fight breast cancer by lowering the amount of estrogen the body makes.
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. It is not yet know whether hormone therapy is more effective when given with or
without everolimus in treating breast cancer.

PURPOSE: This randomized phase III trial studies how well giving hormone therapy together
with or without everolimus work in treating patients with breast cancer.

Based upon the current state of science, the investigators are proposing to conduct a
randomized clinical trial in which participants are randomized post-surgery to either BIS or
circumferential (tape) measurements for follow-up arm measurements. When patients in the BIS
group have an L-Dex change that is ≥10 units higher than the pre-surgical baseline measure,
and when patients in the tape measurement group have a volume change in the at-risk arm that
is between ≥ 5% and arm), both will receive four weeks of 23-32 mm compression sleeve and gauntlet therapy.